Celgene Corp (CELG) 153.03 $CELG
Post-Hoc Analysis of Overall Survival in Phase III MPACT Study of Patients with Advanced Pancreatic Cancer Presented at ASCO 2014
Business Wire - Sun Jun 01, 8:00AM CDT
Celgene Corporation (NASDAQ: CELG) today announced updated Overall Survival (OS) results from a post-hoc analysis of its phase III MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer. A poster discussion of the analysis is scheduled for Sunday, June 1st at 11:30 am CT at the 50th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Ill.
Final Glance: Biotechnology companies
AP - Fri May 30, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Midday Glance: Biotechnology companies
AP - Fri May 30, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Fri May 30, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Biogen Idec
at Investor's Business Daily - Thu May 29, 5:48PM CDT
Biogen Idec (BIIB) rose 4% after JPMorgan upgraded its stock to overweight from neutral, citing positive opinions on oral multiple-sclerosis drug Tecfidera, and hiked its price target to 375 from 300. JPMorgan cut Celgene (CELG) to neutral from...
Scorned Pfizer Should Forget AstraZeneca and Buy Celgene Instead
Todd Campbell, The Motley Fool - Motley Fool - Thu May 29, 5:30PM CDT
AstraZeneca played hard to get and won, at least for now. The British pharmaceutical major this month rejected two nine-figure buyout offers from Pfizer , which now must wait at least three months before making any additional offers. ...
Array BioPharma Collaborates with Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 29, 4:10PM CDT
Array BioPharma (ARRY) announced that it has entered into a drug discovery collaboration agreement with Biogen Idec (BIIB).
Biogen Upgraded, Celgene Downgraded On Pipelines
at Investor's Business Daily - Thu May 29, 2:18PM CDT
Big-cap biotechs Biogen Idec (BIIB) and Celgene (CELG) were headed in opposite directions on the stock market today after JPMorgan upgraded one and downgraded the other. JPMorgan analyst Geoff Meacham lifted his rating on Biogen to overweight from...
Stocks Slightly Higher Amid Mixed Data; S&P 500 Logs New High
at Investor's Business Daily - Thu May 29, 9:32AM CDT
Stocks opened modestly higher Thursday despite mixed economic data. The Nasdaq climbed 0.4% to its best levels since early April. The S&P 500 rose 0.2% to a record high. Meanwhile, the Dow Jones industrial average ticked up 0.1%. Volume was tracking...
Veracyte, Foundation Medicine and Panacea Global Paving Way in Faster, More Accurate Cancer Diagnostics
ACCESSWIRE - Thu May 29, 8:53AM CDT
Whitefish, MT / May 29, 2014 / Most of the science behind disease is only truly understandable by scientists, researchers, and physicians rather than the general population. What everyone does understand is that, in virtually every scenario, early detection is a key to treatment or even survivorship. The life sciences IPO boom that started in 2013 has created some additional wind under the sails of few diagnostics companies, including Veracyte Inc. (NASDAQ: VCYT) and Foundation Medicine Inc. (NASDAQ: FMI), and it should have investors taking a closer look at upstart Panacea Global, Inc. (OTCQB: PANG) and its new cancer-detecting technology.
How Will Celgene (CELG) Stock Be Affected By This Analyst Action?
at The Street - Thu May 29, 7:17AM CDT
Shares of Celgene (CELG) are lower after J.P. Morgan (JPM) downgraded the stock to 'neutral' from 'overweight' and lowered its price target to $170. from $180.
Breakthrough Innovation for Animal Health, Upcoming Conference Presentations, and New Treatment Options for Patients - Analyst Notes on Merck, Actavis, Celgene, Bristol-Myers Squibb and GSK
PR Newswire - Thu May 29, 4:50AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), Bristol-Myers Squibb Co. (NYSE: BMY) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3057-100free.
Cramer: A Market Too Stupid for Words
at The Street - Wed May 28, 10:32AM CDT
It is pretty incredible that identical news can trigger completely different reactions.
After Yesterday's Rally of 3.33% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue May 27, 3:50PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $150.01 to a high of $155.24. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of $151.78 on volume of 4.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Celgene Rises 3.33% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 27, 3:49PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $150.01 to a high of $155.24. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of $151.78 on volume of 4.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
3 Health Care Stocks Nudging The Sector Higher
at The Street - Tue May 27, 12:02PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
2014 Value Investor 500: The Full List
Dan Dzombak, The Motley Fool - Motley Fool - Sat May 24, 8:01AM CDT
The Value Investor 500 is my attempt to highlight the top 500 publicly traded companies in the U.S. To construct a quality-based list of the top 500 companies in the U.S., I focused on what's really important for investors to pay attention to: ...
Post-Hoc Analysis of Overall Survival in Phase III MPACT Study of Patients with Advanced Pancreatic Cancer Presented at ASCO 2014
Business Wire - Sun Jun 01, 8:00AM CDT
Celgene Corporation (NASDAQ: CELG) today announced updated Overall Survival (OS) results from a post-hoc analysis of its phase III MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer. A poster discussion of the analysis is scheduled for Sunday, June 1st at 11:30 am CT at the 50th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Ill.
Final Glance: Biotechnology companies
AP - Fri May 30, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Midday Glance: Biotechnology companies
AP - Fri May 30, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Fri May 30, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Biogen Idec
at Investor's Business Daily - Thu May 29, 5:48PM CDT
Biogen Idec (BIIB) rose 4% after JPMorgan upgraded its stock to overweight from neutral, citing positive opinions on oral multiple-sclerosis drug Tecfidera, and hiked its price target to 375 from 300. JPMorgan cut Celgene (CELG) to neutral from...
Scorned Pfizer Should Forget AstraZeneca and Buy Celgene Instead
Todd Campbell, The Motley Fool - Motley Fool - Thu May 29, 5:30PM CDT
AstraZeneca played hard to get and won, at least for now. The British pharmaceutical major this month rejected two nine-figure buyout offers from Pfizer , which now must wait at least three months before making any additional offers. ...
Array BioPharma Collaborates with Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 29, 4:10PM CDT
Array BioPharma (ARRY) announced that it has entered into a drug discovery collaboration agreement with Biogen Idec (BIIB).
Biogen Upgraded, Celgene Downgraded On Pipelines
at Investor's Business Daily - Thu May 29, 2:18PM CDT
Big-cap biotechs Biogen Idec (BIIB) and Celgene (CELG) were headed in opposite directions on the stock market today after JPMorgan upgraded one and downgraded the other. JPMorgan analyst Geoff Meacham lifted his rating on Biogen to overweight from...
Stocks Slightly Higher Amid Mixed Data; S&P 500 Logs New High
at Investor's Business Daily - Thu May 29, 9:32AM CDT
Stocks opened modestly higher Thursday despite mixed economic data. The Nasdaq climbed 0.4% to its best levels since early April. The S&P 500 rose 0.2% to a record high. Meanwhile, the Dow Jones industrial average ticked up 0.1%. Volume was tracking...
Veracyte, Foundation Medicine and Panacea Global Paving Way in Faster, More Accurate Cancer Diagnostics
ACCESSWIRE - Thu May 29, 8:53AM CDT
Whitefish, MT / May 29, 2014 / Most of the science behind disease is only truly understandable by scientists, researchers, and physicians rather than the general population. What everyone does understand is that, in virtually every scenario, early detection is a key to treatment or even survivorship. The life sciences IPO boom that started in 2013 has created some additional wind under the sails of few diagnostics companies, including Veracyte Inc. (NASDAQ: VCYT) and Foundation Medicine Inc. (NASDAQ: FMI), and it should have investors taking a closer look at upstart Panacea Global, Inc. (OTCQB: PANG) and its new cancer-detecting technology.
How Will Celgene (CELG) Stock Be Affected By This Analyst Action?
at The Street - Thu May 29, 7:17AM CDT
Shares of Celgene (CELG) are lower after J.P. Morgan (JPM) downgraded the stock to 'neutral' from 'overweight' and lowered its price target to $170. from $180.
Breakthrough Innovation for Animal Health, Upcoming Conference Presentations, and New Treatment Options for Patients - Analyst Notes on Merck, Actavis, Celgene, Bristol-Myers Squibb and GSK
PR Newswire - Thu May 29, 4:50AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), Bristol-Myers Squibb Co. (NYSE: BMY) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3057-100free.
Cramer: A Market Too Stupid for Words
at The Street - Wed May 28, 10:32AM CDT
It is pretty incredible that identical news can trigger completely different reactions.
After Yesterday's Rally of 3.33% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue May 27, 3:50PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $150.01 to a high of $155.24. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of $151.78 on volume of 4.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Celgene Rises 3.33% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 27, 3:49PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $150.01 to a high of $155.24. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of $151.78 on volume of 4.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
3 Health Care Stocks Nudging The Sector Higher
at The Street - Tue May 27, 12:02PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
2014 Value Investor 500: The Full List
Dan Dzombak, The Motley Fool - Motley Fool - Sat May 24, 8:01AM CDT
The Value Investor 500 is my attempt to highlight the top 500 publicly traded companies in the U.S. To construct a quality-based list of the top 500 companies in the U.S., I focused on what's really important for investors to pay attention to: ...
